Abstract
Percutaneous treatment of Hydatid Liver Cyst (HLC) with scolicidal agent under ultrasound guidance is now worldwide used after the advent of Percutaneous-Aspiration-Injection and Re-Aspiration (PAIR) and its modifications. Although HLC represent a benign disease, treatment has to be considered mandatory in symptomatic cysts and recommended in viable cysts because of the risk of severe complications. In this article, clinical indications, PAIR technique with results and complications are discussed. Finally, clinical flow-chart of active and inactive HLCs is reported. The present article is a review of some patents in the Hydatid liver cyst.
Keywords: Liver, interventional ultrasound, hydatid liver cyst, percutaneous-aspiration-injection and re-aspiration (PAIR), double-percutaneous-aspiration-and ethanol injection (D-PAI)
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Safety
Current Drug Targets
Infectious Disorders - Drug Targets
Letters in Drug Design & Discovery
Current HIV Research
Current Drug Discovery Technologies
Anti-Infective Agents
Related Books
Frontiers in Clinical Drug Research: Anti-Infectives
Frontiers in Drug Design and Discovery
Frontiers in Anti-Infective Drug Discovery
Coronaviruses
Moving From COVID-19 Mathematical Models to Vaccine Design: Theory, Practice and Experiences
COVID-19: Effects in Comorbidities and Special Populations
An Update on SARS-CoV-2: Damage-response Framework, Potential Therapeutic Avenues and the Impact of Nanotechnology on COVID-19 Therapy
An Epidemiological Update on COVID -19
Frontiers in Cardiovascular Drug Discovery
Frontiers in Drug Design and Discovery
24